Curasight: Extends runway into 2027 with capital raise
Summary
- Curasight has raised approximately DKK 20m through a directed issue, issuing 1,120,605 new shares at DKK 17.80 per share, representing a 10.28% discount to the VWAP from 6 May to 22 June 2026.
- The capital raise results in a 2.27% dilution for non-participating existing shareholders and extends the company's financing horizon to the end of H1 2027.
- Proceeds will support the clinical development of uTRACE® and uTREAT®, including finalizing a next-generation peptide for a basket trial and submitting an IND application to the FDA for uTREAT® in brain cancer.
- The raise strengthens Curasight's position for negotiations with potential partners and prepares for basket studies, enhancing the potential pipeline value.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Curasight this morning announced that it has completed a directed issue of approximately DKK 20m before transaction costs. The issue comprises 1,120,605 new shares at a subscription price of DKK 17.80 per share, set through an accelerated bookbuilding.
The price corresponds to a discount of approximately 10.28% relative to the volume weighted average price (VWAP) over the period from 6 May to 22 June 2026. A range of Nordic and international, institutional and professional investors participated, including both new and existing shareholders.
The issue results in a dilution of approximately 2.27% for existing shareholders who did not participate.
The issue follows in the wake of the encouraging preliminary Phase 1 data from the uTREAT® study, and the proceeds are intended to strengthen working capital and support the continued clinical development of uTRACE® and uTREAT®. The funds will be used among other things to finalize the next-generation peptide for the basket trial, submit an IND application to the FDA for uTREAT® in brain cancer, and prepare the next clinical phases.
On runway, the issue extends the company's financing horizon meaningfully. Management now assesses that the net proceeds are sufficient to fund operations through the end of H1 2027, and in connection with the issue the maturity on the total outstanding loan from Fenja Capital (approximately DKK 35.7m) has been extended in step, from 29 December 2026 to 30 June 2027.
This is a notable extension relative to our previous framing. In our investment case one-pager, we described the company's earlier funding of roughly DKK 46m as securing the runway to execute both the uTREAT® and uTRACE® trials and the regulatory steps through 2026, explicitly excluding a potential basket-trial start.
The current raise pushes runway to the end of H1 2027 and earmarks proceeds precisely for the next-phase preparations, including the basket-trial peptide and the FDA IND, that our prior case had left outside the funded perimeter.
Although completed at a discount in the higher end of what is typically seen in directed issues, and below the current share price (yesterday's close of SEK 21), the raise puts the company in a stronger position to negotiate with potential partners and, more importantly, to begin preparing the basket studies, which will substantially increase the potential pipeline value.
Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis kl. 08:07 d. 23.06.2026.